Copyright
©2006 Baishideng Publishing Group Co.
World J Gastroenterol. Feb 28, 2006; 12(8): 1278-1280
Published online Feb 28, 2006. doi: 10.3748/wjg.v12.i8.1278
Published online Feb 28, 2006. doi: 10.3748/wjg.v12.i8.1278
PatientNo | Age/sex | Disease | Durationof IBD (yr) | Localization | CDAI before/after6 cycles | UC-DAIbefore/after 6 cycles | Maintenancetherapy for remission |
1 | 46/female | CD | 26 | colon-rectum | 168/79 | methotrexate | |
2 | 65/female | CD | 18 | ileum-colon-rectum | 231/86 | methotrexate | |
3 | 49/female | CD | 22 | ileum-colon | 198/91 | methotrexate | |
4 | 36/female | CD | 5 | ileum-colon | 242/98 | methotrexate | |
5 | 59/male | UC | 5 | rectum | 14/6 | azathioprine | |
6 | 44/male | UC | 5 | rectum | 15/8 | azathioprine | |
7 | 29/male | UC | 4 | recto-sigmoid | 13/6 | azathioprine | |
8 | 29/male | UC | 8 | recto-sigmoid | 14/7 | azathioprine |
- Citation: Barta Z, Tóth L, Zeher M. Pulse cyclophosphamide therapy for inflammatory bowel disease. World J Gastroenterol 2006; 12(8): 1278-1280
- URL: https://www.wjgnet.com/1007-9327/full/v12/i8/1278.htm
- DOI: https://dx.doi.org/10.3748/wjg.v12.i8.1278